Cadila Pharmaceuticals and Singapore-based Wellesta Holdings have signed an MoU to establish a joint venture focused on expanding access to high-quality healthcare solutions across Southeast Asia and other emerging markets.
Wellesta Holdings | 01/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy